• Prof.ssa Elisabetta Bugianesi, PI
• Dr.ssa Chiara Rosso, Technician
• Dr. Gian Paolo Caviglia, Research fellow
• Dr.ssa Maria Lorena Abate, Technician
• Dr. Angelo Armandi, PhD student
• Dr.ssa Antonella Olivero
• Dr.ssa Nuria Perez Diaz del Campo, Research fellow
• Dr. Gabriele Castelnuovo, PhD student
• Dr.ssa Marta Guariglia, Research fellow
• Dr.ssa Eleonora Dileo, Research fellow
• Dr.ssa Daphne D'Amato
• Dr.ssa Amina Abdulle
• Dr.ssa Kamela Gjini
• Dr.ssa Aurora Nicolosi, Fellow

Presidio Ospedaliero San Giovanni Antica Sede
Laboratorio di Epatologia e Gastroenterologia Molecolare
Via San Massimo 24 – piano 4
10123 Toriino
e-mail: elisabetta.bugianesi@unito.it
Tel. 0116333532
Fax: 0116333976 (struttura, palazzina, piano, stanza), mail, telefono, fax

• Prof.ssa Elisabetta Bugianesi
• Dr.ssa Antonella Olivero
• Dr.ssa Chiara Rosso
• Dr. Gian Paolo Caviglia
• Dr.ssa Maria Lorena Abate

• Creation of a prospective cohort (cross-sectional and longitudinal) of patients with Non-alcoholic fatty liver disease, NAFLD); collection of clinical anthropometrical, biochemical and histological data and on-line registry update; collection of blood samples (whole blood, serum, plasma), liver tissue, urine and stool samples for the biobank. 
• Study of the pathogenetic mechanisms involved in the onset and progression of NAFLD with a particular focus on the role of metabolic abnormalities and their impact on the progression of liver damage. In vivo studies on liver metabolic flexibility in NAFLD patients by tracers infusion (stable isotope) (in collaboration with the Institute of Clinical Physiology, CNR, Pisa, Prof.ssa Amalia Gastaldelli) 
• Assessment of single nucleotide polymorphisms associated to the risk of NAFLD and to the progression of liver damage and its complicances (i.e. HCC). 
• Validation of non-invasive biomarkers of NASH and hepatic fibrosis. Validation of Imagine techniques (CAP, elastography, RNM) for the non-invasive diagnosis of NASH and hepatic fibrosis. 
• Validation of non-invasive biomarkers of HCC (MIRRA project) 
• Clinical Trials for the treatment of NAFLD: 

- REGENERATE/INTERCEPT “A Phase 3, Double Blind, Randomized, Long-Term, Placebo Controlled, Multicenter Study Evaluating the efficacy of Obeticholic Acid in subjects with Nonalcoholic Steatohepatitis”; 

- INVENTIVA “A randomized, double-blind, placebo-controlled, multicenter, dose range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)” 

- SYNERGY-NASH (LILLY) “A randomized, double-blinded, placebo-controlled phase 2 study comparing the efficacy and safety of tirzepatide vs placebo in patients with NASH”

- BOEHRINGER INGELHEIM “Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatitis (NASH) and fibrosis”

• List of publications of the last 3 years

1. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. Lancet. 2022;399(10319):61-116. doi: 10.1016/S0140-6736(21)01701-3.
2. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. N Engl J Med. 2021;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
3. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Younes R, Caviglia GP, Govaere O, Rosso C, Armandi A, Sanavia T, Pennisi G, Liguori A, Francione P, Gallego-Durán R, Ampuero J, Garcia Blanco MJ, Aller R, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Pareja MJ, Zaki MYW, Grieco A, Fracanzani AL, Valenti L, Miele L, Fariselli P, Petta S, Romero-Gomez M, Anstee QM, Bugianesi E. J Hepatol. 2021;75(4):786-794. doi: 10.1016/j.jhep.2021.05.008.
4. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Møller HJ, Abate ML, Vilstrup H, Gastaldelli A, George J, Grønbæk H, Bugianesi E. J Hepatol. 2019; 71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031.
5. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Younes R, Saponaro C, Buzzigoli E, Caviglia GP, Abate ML, Smedile A, Rizzetto M, Cassader M, Gastaldelli A, Bugianesi E. Hepatology. 2016;63(1):107-16. doi: 10.1002/hep.28287.

National projects

• Medicina di precisione nelle malattie cardiometaboliche mediante omica e big data (Progetto Strategico di Eccellenza Dipartimentale, DSM, UNITO, n. D15D18000410001)
• Impatto del sequenziamento completo dell’esoma sulla gestione clinica del paziente con steatosi epatica non alcolica e malattia epatica criptogenetica (Ricerca Finalizzata RF-2016-02364358)

International projects

• FLIP: Fatty Liver Inhibition of Progression (FP7 HEALTH-F2-2009-241762)
• EPoS: Elucidating Pathways of Steatohepatitis (EU H2020 Program Grant Agreement 634413)
• LITMUS: Liver Investigation Testing Marker Utility in Steatohepatitis (EU/EFPIA IMI2 Grant agreement 777377): https://litmus-project.eu/
• Developing a model of care for risk stratification and management of diabetic patients with non-alcoholic fatty liver disease (NAFLD) (IN-IT-989-5790, GILEAD Sciences)

• European Researchers’ night
• Dissemination activities in schools